Maraviroc FDA Link

A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR. It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane fusion and cellular entry.

Also Known As:

4,4- Difluoro- N- ((1S)- 3- (exo- 3- (3- isopropyl- 5- methyl- 4H- 1,2,4- triazol- 4- yl)- 8- azabicyclo(3.2.1)oct- 8- yl)- 1- phenylpropyl)cyclohexanecarboxamide; Selzentry; UK-427,857; UK-427857; UK 427,857; UK 427857; UK427,857; UK427857; Cyclohexanecarboxamide, 4,4- difluoro- N- ((1S)- 3- ((3- exo)- 3- (3- methyl- 5- (1- methylethyl)- 4H- 1,2,4- triazol- 4- yl)- 8- azabicyclo(3.2.1)oct- 8- yl)- 1- phenylpropyl)-

Organic Chemicals: 140
- Hydrocarbons: 1726
  - Cyclic Hydrocarbons: 96
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        Maraviroc: 338
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Azoles: 2199
    - Triazoles: 1573
      - Maraviroc: 338

M E Bargalló Selected Research

M E Bargalló Research Topics

Disease

Drug/Important Bio-Agent (IBA)